LUMVOA

This brand name is authorized in United States.

Active ingredients

The drug LUMVOA contains one active pharmaceutical ingredient (API):

`1`	Veligrotug UNII `Z9U2SS9ZC8` - VELIGROTUG
	Veligrotug's mechanism of action in patients with thyroid eye disease has not been fully characterized. Veligrotug is a humanized IgG1 monoclonal antibody that binds to IGF-1R and inhibits IGF-1R signaling by blocking ligand-induced receptor autophosphorylation.
	Read more about Veligrotug

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LUMVOA Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
US	FDA, National Drug Code	85166-001

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.